X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.fiercepharma.com/pharma/ns-pharmas-duchenne-therapy-viltepso-fails-confirmatory-trial
https://www.prnewswire.com/news-releases/ns-pharma-shares-preliminary-results-of-viltolarsen-ns-065--ncnp-01-phase-3-clinical-trial-racer53-study-302155379.html
https://www.prnewswire.com/news-releases/ns-pharma-inc-shares-new-viltepso-viltolarsen-data-at-the-mda-clinical--scientific-conference-2024-302080958.html
https://www.prnewswire.com/news-releases/viltepso-viltolarsen-injection-four-year-clinical-trial-data-published-in-the-journal-of-neuromuscular-diseases-301819073.html
https://www.prnewswire.com/news-releases/viltepso-viltolarsen-injection-open-label-extension-clinical-trial-data-scheduled-for-presentation-at-the-mda-clinical--scientific-conference-2023-301775371.html
https://www.prnewswire.com/news-releases/ns-pharma-reports-on-results-of-viltepso-viltolarsen-injection-after-four-years-of-treatment-in-open-label-extension-trial-in-duchenne-muscular-dystrophy-301656722.html
https://www.prnewswire.com/news-releases/viltepso-viltolarsen-injection-four-year-clinical-trial-data-to-be-presented-at-the-world-muscle-society-2022-conference-301640832.html
https://www.prnewswire.com/news-releases/viltepso-viltolarsen-injection-long-term-efficacy-and-safety-data-published-in-the-journal-of-neuromuscular-diseases-301555981.html
https://www.prnewswire.com/news-releases/viltepso-viltolarsen-injection-interim-long-term-clinical-trial-data-scheduled-for-presentation-at-the-world-muscle-society-2021-virtual-conference-301379083.html
https://www.prnewswire.com/news-releases/peer-reviewed-study-suggests-nerivio-effective-for-treatment-of-acute-menstrual-migraine-headache-301316209.html
Market Place
Share 
